Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
SRZN · against 454 other Healthcare companies listed in US-listed
Ranked #412 of 455 · scores higher than 9% of peers
Bars: peers in each 10-point band of the growth score44 peers with a growth score of 0–9, including SRZN · Click a bar to see the companies
Mainly because of its 3-year revenue growth, earnings per share growth and revenue growth, which are weaker than most Healthcare peers.
| Metric | SRZN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 475 reported | -8.8% | 11.0% | 15% | 33% | |
| Earnings per share growthHigher is better · 171 reported | Not reported | 21.2% | — | — | 33% |
| 3-year revenue growthHigher is better · 433 reported | -34.7% | 11.0% | 5% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 460M USD | 100 | 53 | |
| 2 | 1.4B USD | 99 | 73 | |
| 2 | 441M USD | 99 | 81 | |
| 2 | 9.5B USD | 99 | 31 | |
| 2 | 87M USD | 99 | 27 | |
| 410 | 165M USD | 10 | 14 | |
| 410 | 115M USD |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score
| 23 |
| 412 | 4.1B USD | 9 | 24 |
| 412 | 5.8B USD | 9 | 38 |
| 412 | 372M USD | 9 | 14 |
| 415 | 3.7B USD | 8 | 31 |
| 415 | 206M USD | 8 | 36 |
| 415 | 288M USD | 8 | 38 |
| 415 | 2.3B USD | 8 | 27 |